MAP2K7 and melanoma: GSDME expressed by the pyroptostic cell the combined treatment of BRAF and MEK inhibitors in melanoma can elevate the amount of T cells and DCs, while GSDME-deficient melanoma exhibited less HMGB1 release and BRAFi and MEKi resistance [185].